Literature DB >> 17100706

Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)] in transplantation.

Moritz N Wente1, Peter Sauer, Arianeb Mehrabi, Jürgen Weitz, Markus W Büchler, Jan Schmidt, Peter Schemmer.   

Abstract

Non-compliance in solid transplantation recipients is a major factor in acute graft rejection, which influences patient survival. Nowadays, tacrolimus is one of the most widely used immunosuppressant agents together with cyclosporine following kidney and liver transplantation with a standardized twice-daily dosing regimen. To improve the patients' compliance to the prescribed immunosuppressive therapy, FK506E (MR4), a modified release (MR) oral dosage form of tacrolimus has been developed for a once-daily dosing regimen. This report reviews the most recent results of clinical trials with MR tacrolimus after kidney and liver transplantation.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17100706     DOI： 10.1111/j.1399-0012.2006.00605.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN： 0902-0063            Impact factor:   2.863


  7 in total

1.  Pharmacokinetics of tacrolimus converted from twice-daily formulation to once-daily formulation in Chinese stable liver transplant recipients.

Authors:  Yi-fan Zhang; Xiao-yan Chen; Xiao-jian Dai; Xi-sheng Leng; Da-fang Zhong
Journal:  Acta Pharmacol Sin       Date:  2011-10-03       Impact factor: 6.150

Review 2.  Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2015-10       Impact factor: 6.447

3.  Upregulation of neurotrophic factor-related gene expression in retina with experimental autoimmune uveoretinitis by intravitreal injection of tacrolimus (FK506).

Authors:  Keiko Oh-i; Hiroshi Keino; Hiroshi Goto; Naoyuki Yamakawa; Masaru Takeuchi; Masahiko Usui; Takuya Iwasaki
Journal:  Br J Ophthalmol       Date:  2007-10-16       Impact factor: 4.638

Review 4.  Current concepts in transplant surgery: liver transplantation today.

Authors:  A Mehrabi; H Fonouni; S A Müller; J Schmidt
Journal:  Langenbecks Arch Surg       Date:  2008-02-29       Impact factor: 3.445

5.  A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients.

Authors:  Zhengshan Wu; Qingyang Meng; Yongxiang Xia; Feng Zhang; Wei You
Journal:  J Biomed Res       Date:  2013-06-13

6.  Clinical experience with once-daily tacrolimus in de novo kidney transplant recipients from living donors in Japan: 1-year follow up.

Authors:  Kenichiro Ishida; Shinichi Ito; Tomohiro Tsuchiya; Yoshinori Imanishi; Takashi Deguchi
Journal:  Cent European J Urol       Date:  2013-11-18

7.  Effect of delayed CNI-based immunosuppression with Advagraf® on liver function after MELD-based liver transplantation [IMUTECT].

Authors:  Susanne Richter; Georg Polychronidis; Daniel N Gotthardt; Philipp Houben; Thomas Giese; Anja Sander; Colette Dörr-Harim; Markus K Diener; Peter Schemmer
Journal:  BMC Surg       Date:  2014-09-01       Impact factor: 2.102
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.